Clinical trials have been carried out to test medications targeting EMT regulators in HCC, such as TGFR1 inhibitors and c‐MET inhibitors, but only a small portion of patients with specific genetic profiles benefit from these therapies.29, 30, 31. The gene discussed is MET; the disease is hepatocellular carcinoma.